University of Miami gifts its 1994 ibogaine IND to the federal government

Miami just became the center of the ibogaine research map. In August 2026, the University of Miami announced it is gifting its original 1994 ibogaine Investigational New Drug (IND) application to the US Department of Health and Human Services — handing federal researchers a decades-old FDA filing that could speed regulatory review of new clinical work.

The IND dates back to the university's pioneering ibogaine research program of the 1990s, the first formal US effort to study the compound in people with substance use disorders. The Multidisciplinary Association for Psychedelic Studies (MAPS), which provided the first outside funding for that program, called the transfer a standard-setting act of open science.

Why an old application matters

An IND is the regulatory foundation on which human trials are built. By placing the 1994 filing in federal hands rather than letting it sit in a private archive, the university gives publicly funded researchers a documented starting point — historical pharmacology, dosing, and safety observations — that would otherwise take years to reconstruct.

The gift follows new federal policies prioritizing psychedelic research, including an April 2026 executive order streamlining study of certain drugs and expanding 'right to try' access to experimental medications. MAPS has also published a free Ibogaine Investigator's Brochure covering three decades of data as a companion resource, while noting the 1994 filing is no substitute for current safety and sourcing data.

The University of Miami's wider psychedelic program

The transfer is not an isolated gesture. University of Miami epidemiologist Denise Vidot and her team are examining how psychedelic substances interact with sleep, inflammation, and overall health, positioning the university within a new wave of federally encouraged therapeutic research.

For South Florida, the symbolism is significant: the region's flagship research university is now formally linked to the reopening of ibogaine science at the federal level, even as the compound itself remains Schedule I and no legal treatment program operates in Florida.

What it means for patients

In the short term, nothing changes clinically — ibogaine remains investigational, and treatment still happens abroad or in research settings. But the move shortens the plausible path to regulated US trials, and it signals that ibogaine is finally being treated as a subject of serious federal science rather than a fringe curiosity.

We will continue tracking trial registrations and regulatory developments. Nothing here is medical advice — anyone considering ibogaine should consult a licensed physician and review our safety overview.